Compare ZGN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGN | MIRM |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.7B |
| IPO Year | N/A | 2019 |
| Metric | ZGN | MIRM |
|---|---|---|
| Price | $10.48 | $65.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $10.98 | ★ $87.55 |
| AVG Volume (30 Days) | ★ 581.9K | 560.0K |
| Earning Date | 09-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $2,248,050,499.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $5.08 | $19.91 |
| P/E Ratio | $24.10 | ★ N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $6.05 | $36.88 |
| 52 Week High | $11.00 | $78.55 |
| Indicator | ZGN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 36.47 |
| Support Level | $10.12 | $63.66 |
| Resistance Level | $11.00 | $66.77 |
| Average True Range (ATR) | 0.29 | 2.99 |
| MACD | -0.01 | -0.66 |
| Stochastic Oscillator | 54.64 | 13.68 |
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.